0001485003-21-000190.txt : 20210915 0001485003-21-000190.hdr.sgml : 20210915 20210915080029 ACCESSION NUMBER: 0001485003-21-000190 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20210909 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20210915 DATE AS OF CHANGE: 20210915 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sesen Bio, Inc. CENTRAL INDEX KEY: 0001485003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262025616 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36296 FILM NUMBER: 211254278 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-444-8550 MAIL ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Eleven Biotherapeutics, Inc. DATE OF NAME CHANGE: 20100223 8-K 1 sesn-20210909.htm 8-K sesn-20210909
False000148500300014850032021-09-092021-09-09

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 9, 2021
 
 
SESEN BIO, INC.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware001-3629626-2025616
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
245 First Street, Suite 1800
Cambridge, MA
02142
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (617) 444-8550
Not Applicable
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
 
Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
 
Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))
 
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001SESNThe Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
                            Emerging growth company     

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                                 ¨




Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 9, 2021, the Board of Directors (the “Board”) and the Compensation Committee of Sesen Bio, Inc. (the “Company”) approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the “Retention Program”).

Pursuant to the Retention Program and effective as of October 1, 2021, the Company’s non-executive employees will receive a combination of a cash bonus award and a one-time restricted stock unit (“RSU”) award which vests in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company’s common stock. In connection with the Retention Program, the Board and the Compensation Committee also approved certain severance benefits for non-executive employees.

Also pursuant to the Retention Program and effective as of October 1, 2021, the Company’s executive officers, except for the Chief Executive Officer, will be granted a one-time performance-based restricted stock unit (“PSU”) award equal to the value of approximately fifty percent of current base salary. Each PSU represents a contingent right to receive one share of the Company’s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. The Company’s chief financial officer, Monica Forbes, will be awarded PSUs in an amount equal to half of her current base salary ($190,375) divided by the closing price of the Company’s common stock on October 1, 2021 but not less than $1. The Company’s chief technology officer, Glen MacDonald, will be awarded PSUs in an amount equal to half of his current base salary ($186,400) divided by the closing price of the Company’s common stock on October 1, 2021 but not less than $1. Equity awards granted under the Retention Program will be made pursuant to the Company’s 2014 Stock Incentive Plan, as amended, previously filed with the Securities and Exchange Commission.

Sesen Bio remains committed to its mission of saving and improving the lives of patients with cancer and believes the retention of the Company’s talented employees is critical to realizing this mission. The Company continues to believe in the safety and efficacy data of Vicineum™ as it prepares for the chemistry, manufacturing and controls (“CMC”) and clinical Type A meetings with the US Food and Drug Administration (“FDA”) anticipated in the fourth quarter of 2021.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, statements regarding the ability of the Company to retain its current employees, the Company’s belief in the safety and efficacy data of Vicineum, and the Company’s preparations for, and the timing of, the Type A meetings with the FDA to discuss Vicineum, which are based on the Company’s current expectations and inherently involve significant risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including the risk that the Company’s retention program may not be successful at retaining current employees, unanticipated difficulties with retaining current employees, the risk that the FDA may not schedule Type A meetings with the Company to discuss Vicineum in the fourth quarter of this year, or at all, and the risk that the Company may not resume its plans to pursue regulatory approval for Vicineum in the US, among other risks and uncertainties. A further description of the risks and uncertainties relating to the business of the Company is contained in the Company’s most recent annual report on Form 10-K and the Company’s quarterly reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the Securities and Exchange Commission. The Company undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information, future events or changes in its expectations.




SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 15, 2021
 
Sesen Bio, Inc.
By:/s/ Thomas R. Cannell, D.V.M.
Thomas R. Cannell, D.V.M.
President and Chief Executive Officer



EX-101.SCH 2 sesn-20210909.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 sesn-20210909_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Type Document Type Entity Address, Postal Zip Code Entity Address, Postal Zip Code Local Phone Number Local Phone Number Amendment Flag Amendment Flag Written Communications Written Communications City Area Code City Area Code Title of 12(b) Security Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Soliciting Material Soliciting Material Document Period End Date Document Period End Date Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Cover [Abstract] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line Two Entity Address, Address Line Two Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol EX-101.PRE 4 sesn-20210909_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 sesn-20210909_htm.xml IDEA: XBRL DOCUMENT 0001485003 2021-09-09 2021-09-09 false 0001485003 8-K 2021-09-09 SESEN BIO, INC. DE 001-36296 26-2025616 245 First Street Suite 1800 Cambridge MA 02142 617 444-8550 false false false false Common Stock, par value $0.001 SESN NASDAQ false XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Sep. 09, 2021
Cover [Abstract]  
Document Type 8-K
Entity Registrant Name SESEN BIO, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36296
Entity Tax Identification Number 26-2025616
Entity Address, Address Line One 245 First Street
Entity Address, Address Line Two Suite 1800
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 444-8550
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol SESN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001485003
Amendment Flag false
Document Period End Date Sep. 09, 2021
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( E +U,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " )0"]3X.FS;NX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)^FB:.CFHGA2$%Q0O(5D=C=LTX1DI-VW-ZV[740?P&-F_GSS M#4QKHC0AX4L*$1,YS%>C[_HL35RS/5&4 -GLT>MS08T\91"V J6EB M/(Y="Q? !"-,/G\7T"[$N?HG=NX .R7'[);4, SUL)IS90LS MZ=Y@^96=I&/$-3M/?EO=/VP>F6IX(RI^5XGKC6@DYU+621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M E +U/' 6X8/00 , 0 8 >&PO=V]R:W-H965T&UL MG9AO;^HV%,9?WWT*"^W%)M'F#X'2*XI$*;U#]Y:RANU*F_;") :L)G9F.P6^ M_8X#)$P+)^W>$#O)>?*S??S89K"5ZE5O&#-DER9"W[4VQF2?'4='&Y92?2TS M)N#)2JJ4&JBJM:,SQ6A&'O#&0XRNF8A,[]E9';7]BQ005@)!-=_)+MX=T@ M:)$HUT:FQV @2+DX7.GNV!%G 1WO0H!_#/ +[L.'"LH':NAPH.26*/LVJ-E" MT=0B&N"XL*,2&@5/.<29X5B^,35P#$C9&TYT#+L_A/D7PD*671/WMDU\U_?^ M'>X 08GAEQA^H=?!,,B?HZ4V"@;J+T2R4TIV"LG@@N2#C')('T,6^XS5M1 / M[U]]12""$B) 52;"<+,G+VS-;KG$M+B[^,$$(>R5A[SV$CSQA9):G MR_H\Q35*(X5T[I]*I!O\!YY%K6CB"OZ01=Z7VD#::' 8!#(VQ+R]O]#+K:R M#A)7#',.&>OU71?!\]S*#MT/ 8YM#>;#0FY%K4WBMX-!E(M!A[NXM]D!'TRWTB!.5J#2! $5_UN%TWW:A'P<*/^ MKK@Q3$#'I&DNCGZF:ZEPH15--)KDE>M[N&6',N$1-URLR1.DM^(TJ>7!51IY M*M?W<).>*W850?K"^.'ZS6258;OX?[\'[*IUCF0-0+B MLHV E=E[N#M: M'ER@L9,JH_<;=N2GT] <'%7&9")B @?&^JS"I8JSWVW[AT^?+AW^G+/SJ#W; M/U&;-)HD; 6*[O4-?$ =CLN'BI%9<41=2@,'WJ*X811,S+X SU=2FE/%GGK+ M/RV&_P!02P,$% @ "4 O4Y^@&_"Q @ X@P T !X;"]S='EL97,N M>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG M:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1< M>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6 ME :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,H MH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+ M3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC M%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8 M\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W M5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76 M^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1G MA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ M;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^: M0ERHY_U=3_ 102P,$% @ "4 O4Y>*NQS $P( L M !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,. M\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'B4?'D78FYJD6:> MIK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DH MV1%[A$O\G7D(GP&LK M\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N M5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!Y MU!Y:YU;*O8=7LN48Y0]02P,$% @ "4 O4R0>FZ*M ^ $ !H M !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL M[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C] MLCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP M3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( E +U-ED'F2&0$ ,\# M 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@ M"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0" M50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M- M\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[ M0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TF MGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM M;%!+ 0(4 Q0 ( E +U/' 6X8/00 , 0 8 " @0T( M !X;"]W;W)K&PO&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " )0"]399!YDAD! #/ P $P M@ &*$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #4$P " ! end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.sesenbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports sesn-20210909.htm sesn-20210909.xsd sesn-20210909_lab.xml sesn-20210909_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sesn-20210909.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "sesn-20210909.htm" ] }, "labelLink": { "local": [ "sesn-20210909_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "sesn-20210909_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "sesn-20210909.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sesn", "nsuri": "http://www.sesenbio.com/20210909", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sesn-20210909.htm", "contextRef": "i7c44d90a7f5f4947a0ed895fcbec7f2e_D20210909-20210909", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.sesenbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sesn-20210909.htm", "contextRef": "i7c44d90a7f5f4947a0ed895fcbec7f2e_D20210909-20210909", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001485003-21-000190-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001485003-21-000190-xbrl.zip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